Collplant Biotechnologies Ltd (CLGN)

NASDAQ
Currency in USD
1.98
+0.23(+13.14%)
Closed·
CLGN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
1.752.12
52 wk Range
1.556.22
Key Statistics
Edit
Prev. Close
1.74
Open
1.75
Day's Range
1.75-2.12
52 wk Range
1.55-6.22
Volume
26.34K
Average Vol. (3m)
11.04K
1-Year Change
-72.56%
Book Value / Share
1.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CLGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.00
Upside
+607.07%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Collplant Biotechnologies Ltd Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company’s products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds. The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Collplant Biotechnologies Ltd Earnings Call Summary for Q4/2024

  • Q4 2024 EPS of -$0.34 missed forecast of -$0.275; revenue of $164,000 fell short of $432,000 expectation
  • Full-year revenue decreased to $515,000 from $11 million in 2023; net loss of $16.6 million or $1.45 per share
  • Stock price declined 0.68% to $2.78, near 52-week low; analysts maintain $14 price target
  • Company focuses on expanding Virgenix STR distribution in Europe and Asia; optimizing regenerative breast implants
  • Cash position expected to last through Q2 2026; $2 million payment received from AbbVie in February 2025
Last Updated: 03/26/2025, 10:48 AM
Read Full Transcript

Compare CLGN to Peers and Sector

Metrics to compare
CLGN
Peers
Sector
Relationship
P/E Ratio
−1.2x−6.7x−0.5x
PEG Ratio
0.01−0.050.00
Price / Book
1.5x2.2x2.6x
Price / LTM Sales
38.7x8.3x3.0x
Upside (Analyst Target)
-387.8%54.7%
Fair Value Upside
Unlock21.8%8.4%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 14.00
(+607.07% Upside)

Earnings

Latest Release
Mar 26, 2025
EPS / Forecast
-0.33 / -0.275
Revenue / Forecast
165.00K / 432.00K
EPS Revisions
Last 90 days

FAQ

What Is the Collplant ADR (CLGN) Stock Price Today?

The Collplant ADR stock price today is 1.98

What Stock Exchange Does Collplant ADR Trade On?

Collplant ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Collplant ADR?

The stock symbol for Collplant ADR is "CLGN."

What Is the Collplant ADR Market Cap?

As of today, Collplant ADR market cap is 19.93M.

What Is Collplant ADR's Earnings Per Share (TTM)?

The Collplant ADR EPS (TTM) is -1.45.

When Is the Next Collplant ADR Earnings Date?

Collplant ADR will release its next earnings report on May 28, 2025.

From a Technical Analysis Perspective, Is CLGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.